pharma · Obesity · Type 2 diabetes
NovoThirteen
NovoThirteen is a pharma organization headquartered in Bagsværd, JP. Primary therapeutic focus areas include Obesity, Type 2 diabetes, Type 2 Diabetes, Mild cognitive impairment (MCI) or mild dementia, both of the Alzhei
Bagsværd, JP HQ
PMDA registrant Type
Company details
- Status
- Public
- HQ
- Bagsværd, JP
- Programs
- 94
- Drugs
- 67
- Patents
- 0
Etavopivat A 200 mg
Phase 3 · small molecule · Sickle Cell Disease and Thalassaemia
Etavopivat A 200 mg for Sickle Cell Disease and Thalassaemia is a Phase 3 program (small_molecule) at NovoThirteen with 1 ClinicalTrials.gov record(s).
Internal code NN7535-7822
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NovoThirteen
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Sickle Cell Disease and Thalassaemia
- Status
- active
- Trials
- 1